Management of Hypertension in Athletes

  • Shafeeq Ahmed
  • Paul D. Thompson


Athletes have a lower incidence of high blood pressure than nonathletes, but the prevalence of hypertension among athletes is only 50% less than that in the general population [1]. Further, the risk of hypertension may actually be increased in some athletes and physically active individuals because of increased body mass. Indeed, hypertension is the most common cardiovascular problem in athletes.


Calcium Channel Blocker Renal Artery Stenosis Loop Diuretic Target Organ Damage Secondary Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lehmann M, Durr H, Merkelbach H, Schmid A. Hypertension and sports activities: institutional experience. Clin Cardiol 1990;13(3):197–208.PubMedCrossRefGoogle Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206–1252.PubMedCrossRefGoogle Scholar
  3. 3.
    Pickering TG White coat hypertension. Curr Opin Nephrol Hypertens 1996;5(2):192–198.PubMedCrossRefGoogle Scholar
  4. 4.
    Hanson P, Andrea BE. Treatment of hypertension in athletes. In:a DeLee J. Drez D. Starits ki CL, eds. Orthopaedic Sports Medicine: Principles and Practice. Philadelphia, Saunders, 1994:307–319.Google Scholar
  5. 5.
    Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med 2004;350(18):1862–1871.PubMedCrossRefGoogle Scholar
  6. 6.
    Moore TA, Sorokin AV, Hirst C, Thornton-Thompson S, Thompson PD. The accuracy of aneroid sphygmomanometers in the ambulatory setting. Prev Cardiol 2008;11(2):90–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Samenuk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77(1):12–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344(1):3–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001;135(12):1019–1028.PubMedGoogle Scholar
  10. 10.
    USADA guide to prohibited classes of substances and prohibited methods of doping. www. 2008. 10-3-2001.
  11. 11.
    Fuentes RJ, Rosenberg JM. Athletic drug reference “99: complies with NCAA and USOC rules. Clean Data. Durhan, NC, Glaxco Wellcome. 2008:28–36, 52–54, 317–408.Google Scholar
  12. 12.
    IOC prohibited classes of substances and prohibited methods of doping. 10-2-2001.Google Scholar
  13. 13.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265(24):3255–3264.Google Scholar
  14. 14.
    Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276(23):1886–1892.PubMedCrossRefGoogle Scholar
  15. 15.
    Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997;315(7101):154–159.PubMedCrossRefGoogle Scholar
  16. 16.
    Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1(8442):1349–1354.PubMedCrossRefGoogle Scholar
  17. 17.
    Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338(8778):1281–1285.PubMedCrossRefGoogle Scholar
  18. 18.
    Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002;347(8):621–622.PubMedCrossRefGoogle Scholar
  19. 19.
    Martin U, Foreman MA, Travis JC, Casson D, Coleman JJ (2008) Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 33(5):507–511.PubMedCrossRefGoogle Scholar
  20. 20.
    Chick TW, Halperin AK, Gacek EM. The effect of antihypertensive medications on exercise performance: a review. Med Sci Sports Exerc 1988;20(5):447–454.PubMedGoogle Scholar
  21. 21.
    ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283(15):1967–1975.Google Scholar
  22. 22.
    Kaplan NM, Gidding SS, Pickering TG, Wright JT Jr. Task Force 5: systemic hypertension. J Am Coll Cardiol 2005;45(8):1346–1348.PubMedCrossRefGoogle Scholar
  23. 23.
    Pickering TG. Measurement of blood pressure in and out of the office. J Clin Hypertens (Greenwich) 2005;7(2):123–129.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Cardiovascular Services HospitalistHartford HospitalHartfordUSA

Personalised recommendations